Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

Cell Death and Differentiation, Journal Year: 2018, Volume and Issue: 25(3), P. 486 - 541

Published: Jan. 23, 2018

Over the past decade, Nomenclature Committee on Cell Death (NCCD) has formulated guidelines for definition and interpretation of cell death from morphological, biochemical, functional perspectives. Since field continues to expand novel mechanisms that orchestrate multiple pathways are unveiled, we propose an updated classification subroutines focusing mechanistic essential (as opposed correlative dispensable) aspects process. As provide molecularly oriented definitions terms including intrinsic apoptosis, extrinsic mitochondrial permeability transition (MPT)-driven necrosis, necroptosis, ferroptosis, pyroptosis, parthanatos, entotic death, NETotic lysosome-dependent autophagy-dependent immunogenic cellular senescence, mitotic catastrophe, discuss utility neologisms refer highly specialized instances these processes. The mission NCCD is a widely accepted nomenclature in support continued development field.

Language: Английский

---

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Nature Reviews Drug Discovery, Journal Year: 2019, Volume and Issue: 18(3), P. 197 - 218

Published: Jan. 4, 2019

Language: Английский

---

Prospects for combining targeted and conventional cancer therapy with immunotherapy

Nature reviews. Cancer, Journal Year: 2017, Volume and Issue: 17(5), P. 286 - 301

Published: March 24, 2017

Language: Английский

---

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

Nature Reviews Clinical Oncology, Journal Year: 2015, Volume and Issue: 13(4), P. 228 - 241

Published: Dec. 15, 2015

Language: Английский

---

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

Immunological Reviews, Journal Year: 2017, Volume and Issue: 276(1), P. 121 - 144

Published: March 1, 2017

Summary Cancers are able to grow by subverting immune suppressive pathways, prevent the malignant cells as being recognized dangerous or foreign. This mechanism prevents cancer from eliminated system and allows disease progress a very early stage lethal state. Immunotherapies newly developing interventions that modify patient's fight cancer, either directly stimulating rejection‐type processes blocking pathways. Extracellular adenosine generated ectonucleotidases CD 39 73 is “immune checkpoint mediator” interferes with anti‐tumor responses. In this review, we focus on ectoenzymes encompass aspects of biochemistry these molecules well detailing distribution function cells. Effects inhibition in preclinical clinical studies discussed. Finally, provide insights into potential application adenosinergic other purinergic‐targeting therapies forecast how might develop combination anti‐cancer modalities.

Language: Английский

---

Metabolic Interactions in the Tumor Microenvironment

Trends in Cell Biology, Journal Year: 2017, Volume and Issue: 27(11), P. 863 - 875

Published: July 19, 2017

Language: Английский

---

Breast Cancer Immunotherapy: Facts and Hopes

Clinical Cancer Research, Journal Year: 2017, Volume and Issue: 24(3), P. 511 - 520

Published: Aug. 12, 2017

Abstract Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed clinical activity programmed cell death-1/programmed death ligand-1 (PD-1/PD-L1) antagonists in small numbers patients with metastatic breast cancer. Clinical appears more likely if tumor triple negative, PD-L1+, and/or harbors higher levels tumor-infiltrating leukocytes. Responses to atezolizumab pembrolizumab appear be durable triple-negative cancer (TNBC), suggesting that these agents may transform lives responding patients. Current efforts are focused on developing immunotherapy combinations convert nonresponders responders, deepen those responses do occur, surmount acquired resistance immunotherapy. Identifying biomarkers can predict potential for response single-agent immunotherapy, identify best a particular patient, guide salvage progressive disease high priorities development. Smart trials testing rational include robust biomarker evaluations will accelerate progress, moving us closer effective almost all Clin Cancer Res; 24(3); 511–20. ©2017 AACR.

Language: Английский

---

Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer

Pharmacology & Therapeutics, Journal Year: 2016, Volume and Issue: 164, P. 152 - 169

Published: April 30, 2016

Insufficient tissue oxygenation, or hypoxia, contributes to tumor aggressiveness and has a profound impact on clinical outcomes in cancer patients. At decreased oxygen tensions, hypoxia-inducible factors (HIFs) 1 2 are stabilized mediate hypoxic response, primarily by acting as transcription factors. HIFs exert differential effects growth affect important hallmarks including cell proliferation, apoptosis, differentiation, vascularization/angiogenesis, genetic instability, metabolism, immune responses, invasion metastasis. As consequence, resistance chemo- radiotherapy associated with poor prognosis Intriguingly, perivascular cells can also express HIF-2α, thereby forming "pseudohypoxic" phenotype that further aggressiveness. Therefore, therapeutic targeting of the potential improve treatment efficacy. Different strategies target and/or include hypoxia-activated prodrugs inhibition HIF dimerization, mRNA protein expression, DNA binding capacity, transcriptional activity. Here we review functions progression malignant solid tumors. We highlight how may be targeted management patients therapy-resistant metastatic cancer.

Language: Английский

---

Navigating metabolic pathways to enhance antitumour immunity and immunotherapy

Nature Reviews Clinical Oncology, Journal Year: 2019, Volume and Issue: 16(7), P. 425 - 441

Published: March 26, 2019

Language: Английский

---

Turning cold tumors into hot tumors by improving T-cell infiltration

Theranostics, Journal Year: 2021, Volume and Issue: 11(11), P. 5365 - 5386

Published: Jan. 1, 2021

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend on infiltration T cells capable recognizing and killing cells. ICIs are not effective in "cold tumors", which characterized lack T-cell infiltration. To realize full potential immunotherapy solve this obstacle, it is essential to understand drivers into tumors. We present a critical review our understanding mechanisms underlying including impaired priming deficient homing beds. "Hot tumors" with significant associated better ICI efficacy. In review, we summarize multiple strategies that promote transformation "hot discuss these lead increased Finally, application nanomaterials provide an outlook future emerging field. The combination nanomedicines enhances cross-presentation antigens promotes A deeper opens new possibilities for development cell-based therapies improve effectiveness.

Language: Английский

---